Next Article in Journal
The Development of a New Shock Absorbing Uniaxial Graded Auxetic Damper (UGAD)
Previous Article in Journal
A Comparative Study of Localized Corrosion and Stress Corrosion Cracking of 13Cr Martensitic Stainless Steel Using Acoustic Emission and X-ray Computed Tomography
Previous Article in Special Issue
Overview of Carbon Nanotubes for Biomedical Applications
Article Menu

Export Article

Open AccessArticle

[60]Fullerene for Medicinal Purposes, A Purity Criterion towards Regulatory Considerations

1
LETIAM, EA7357, IUT d’Orsay, Université Paris Sud, Plateau de Moulon, 91400 Orsay, France
2
Faculté de Pharmacie, Université Paris Descartes, Université Sorbonne Paris Cité, 4 Avenue de l’Observatoire, 75006 Paris, France and Normandie Université, Laboratoire SMS—EA 3233, Université de Rouen, 76821 Mont Saint Aignan, France
3
Grup de Caracterització de Materials, Departament de Física and Barcelona Research Center in Multiscale Science and Engineering, Universitat Politènica de Catalunya, EEBE, Campus Diagonal-Besòs, Av. Eduard Maristany 10-14, 08019 Barcelona, Catalonia, Spain
*
Author to whom correspondence should be addressed.
Materials 2019, 12(16), 2571; https://doi.org/10.3390/ma12162571
Received: 19 June 2019 / Revised: 20 July 2019 / Accepted: 1 August 2019 / Published: 12 August 2019
  |  
PDF [2795 KB, uploaded 12 August 2019]
  |     |  

Abstract

Since the early nineties countless publications have reported promising medicinal applications for [60]fullerene (C60) related to its unparalleled affinity towards free radicals. Yet, until now no officially approved C60-based drug has reached the market, notably because of the alleged dangers of C60. Nevertheless, since the publication of the effects of C60 on the lifespan of rodents, a myriad of companies started selling C60 worldwide for human consumption without any approved clinical trial. Nowadays, several independent teams have confirmed the safety of pure C60 while demonstrating that previously observed toxicity was due to impurities present in the used samples. However, a purity criterion for C60 samples is still lacking and there are no regulatory recommendations on this subject. In order to avoid a public health issue and for regulatory considerations, a quality-testing strategy is urgently needed. Here we have evaluated several analytical tools to verify the purity of commercially available C60 samples. Our data clearly show that differential scanning calorimetry is the best candidate to establish a purity criterion based on the sc-fcc transition of a C60 sample (Tonset ≥ 258 K, ∆sc-fccH ≥ 8 J g−1). View Full-Text
Keywords: fullerene; C60; purity; differential scanning calorimetry (DSC); gas chromatography mass spectrometry (GC-MS); nanomaterials; nanomedicine fullerene; C60; purity; differential scanning calorimetry (DSC); gas chromatography mass spectrometry (GC-MS); nanomaterials; nanomedicine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Keykhosravi, S.; Rietveld, I.B.; Couto, D.; Tamarit, J.L.; Barrio, M.; Céolin, R.; Moussa, F. [60]Fullerene for Medicinal Purposes, A Purity Criterion towards Regulatory Considerations. Materials 2019, 12, 2571.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Materials EISSN 1996-1944 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top